Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Crispr Therapeutics AG (CRSP) vs AT&T Inc. (T) Price & Performance

Crispr Therapeutics AGTrade

Price performance (Past 24H)

Key statistics

Crispr Therapeutics AG vs AT&T Inc. — how do they compare? Crispr Therapeutics AG trades at $53.9 (market cap $5.23B), while AT&T Inc. trades at $24.42 (market cap $167.88B). The key difference: AT&T Inc. is far larger — about 32.1× Crispr Therapeutics AG's market cap, and AT&T Inc. pays a 4.53% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.

CRSPT
Market Cap
$5.23B$167.88B
Sector
HealthMedia
52-Week High
$76.78$29.62
52-Week Low
$44.34$20.49
Enterprise Value
$3.65B$313.20B
Dividend Yield
4.53%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP

About AT&T Inc.

AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.

Read more on T